Soverine

Quick links to important sections

Soverine

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Soverine

What is Soverine?

Soverine is a pharmaceutical medication classified as a selective serotonin reuptake inhibitor (SSRI). It is primarily used in the management and treatment of various mental health conditions, most notably major depressive disorder and several types of anxiety disorders.

Mechanism of Action

The active therapeutic process of Soverine involves the modulation of serotonin levels within the brain. Serotonin is a neurotransmitter—a chemical messenger—responsible for regulating mood, sleep, and emotional stability. By inhibiting the reabsorption (reuptake) of serotonin into the nerve cells, the medication increases the availability of this neurotransmitter in the synaptic gap between neurons. This enhancement of serotonergic activity is associated with the improvement of mood and the reduction of symptoms related to anxiety and depression.

Therapeutic Use

Soverine is utilized to address clinical symptoms that impact daily functioning and emotional well-being. It is designed for long-term stabilization rather than immediate symptom relief, as the physiological adjustments in the brain typically occur over a period of several weeks.

Commonly addressed conditions include:

  • Major Depressive Disorder: Characterized by persistent low mood and loss of interest.
  • Generalized Anxiety Disorder: Involving chronic, excessive worry about various aspects of life.
  • Panic Disorder: Marked by sudden episodes of intense fear and physical symptoms.
  • Social Anxiety Disorder: Defined by significant fear in social or performance-based situations.

Nature of the Medication

As a psychotropic medication, Soverine acts on the central nervous system. It is part of a broader therapeutic approach that may include psychological support and lifestyle adjustments. The medication is formulated to maintain a steady concentration in the bloodstream to ensure consistent neurological effects.

What side effects are possible with Soverine?

Possible Side Effects and Safety Information

Official regulatory documents classify the adverse reactions associated with Alverine (Soverine) across several system-organ classes, though many are categorized with a frequency of Not Known (meaning the frequency cannot be estimated from available data).

Commonly Documented Adverse Reactions

Adverse effects noted in regulatory records typically involve the following organ systems:

  • Nervous System Disorders: Includes reactions such as headache and dizziness.
  • Gastrointestinal Disorders: The most frequent gastrointestinal effect is nausea.
  • Skin and Subcutaneous Tissue Disorders: Reactions may include rash and itching (pruritus).

Serious Adverse Reactions and Safety Restrictions

Rare but serious reactions officially documented include severe allergic responses and liver issues. These serious adverse reactions are:

  • Anaphylaxis and other severe allergic reactions (e.g., dyspnoea/wheezing).
  • Hepatitis (liver inflammation) or Jaundice (yellowing of the skin/eyes). The regulatory text notes that this hepatobiliary effect typically resolves upon cessation of treatment.

Key Safety Limitations

The medicine is contraindicated and should not be used in patients with a known hypersensitivity to the active ingredient or in the presence of certain severe pre-existing gastrointestinal conditions, specifically paralytic ileus or intestinal obstruction.

Population-Specific Safety Notes

  • Pregnancy and Lactation: Use is contraindicated or not recommended due to limited data supporting its safety in these populations.
  • Operating Machinery: As dizziness may occur, individuals are officially advised to avoid driving or operating machinery if affected. The medicine is not recommended for children under the age of 12 years.

This official safety information is structured to define the potential for systemic effects, particularly concerning the immune system and the liver, and establishes clear regulatory boundaries for use in specific populations and clinical scenarios.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Soverine (Alverine citrate) describes specific clinical manifestations and requires mandatory emergency actions in the event of an overdose.

Documented Overdose Manifestations and Risks

An overdose may be characterized by significant physiological effects, including hypotension, which is an officially documented drop in blood pressure. The prescribing information also notes the presence of atropine-like toxic effects.

These effects specifically target the nervous and cardiovascular systems, presenting as symptoms such as confusion, fast heart rate, hallucinations, dizziness, blurred vision, and dilated pupils. Regulatory documents state that fatality is a possible severe outcome following very high-dose exposure, underscoring the life-threatening risk associated with severe overdose.

Mandatory Emergency Actions

Regulatory authorities require patients to seek immediate medical attention for any suspected overdose. It is mandated that you contact your doctor or nearest hospital emergency department immediately and bring the product packaging and any remaining capsules for assessment. Management is supportive and symptomatic, with protocols directed at stabilizing the manifestations, such as providing supportive therapy for hypotension, as detailed in the official regulatory protocol. No specific antidote for Alverine is explicitly named in the official label.

Therapeutic Uses of Soverine

What Soverine Treats: Main Uses and Benefits

This category of medication is generally used to help with symptoms related to physical discomfort in the throat and mouth. It is primarily relevant for easing conditions characterized by temporary, acute, or episodic manifestations. These manifestations often include symptoms related to physical discomfort, such as sore throat pain, painful swallowing, or vocal discomfort and hoarseness.

Soverine is commonly used in clinical scenarios where symptoms interfere with daily functioning, such as during phases of colds or flu when pain becomes more noticeable. It provides a supportive therapeutic benefit by easing discomfort.

“Applied in clinical settings that involve acute or unstable symptom patterns, it is relevant when supportive symptom management is appropriate.”

The medication may assist with easing the overall symptom load, which contributes to improved comfort during these periods of heightened symptoms. This supports patients during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Symptomatic Support for Minor Pain and Irritation


Eligibility and Restrictions for Use

Soverine (Alverine Citrate) eligibility is strictly defined by regulatory documents, distinguishing between permitted use, restrictions, and absolute contraindications.

Populations Prohibited from Use The medicine is strictly contraindicated for patients with specific, life-threatening gastrointestinal conditions, including paralytic ileus and intestinal obstruction. Absolute prohibition also applies to individuals with documented hypersensitivity to the active substance or excipients.

Age, Reproduction, and Conditional Eligibility Use is officially not recommended in children below the age of 12 years. Furthermore, the medicine is contraindicated during pregnancy and lactation, a regulatory restriction due to insufficient data establishing safety in these populations. Eligibility is also subject to conditional use restrictions: the product should not be recommended for hypotensive patients, and initial use is restricted when a patient presents with new or severe symptoms, such as unexplained weight loss or fever, requiring a mandatory medical assessment before therapy begins.

Connection to the overall eligibility profile Regulatory documents establish clear lines of exclusion by setting absolute contraindications for serious pre-existing conditions and prohibiting use in specific non-adult and reproductive populations, ensuring use is confined to populations where the safety profile is established.

What should I know about interactions with other medicines?

Soverine Interactions with other medicines and products

The official regulatory profile for Soverine, whose active ingredient is Alverine citrate, is characterized by a low burden of formally listed drug-drug contraindications. The documented interaction patterns primarily relate to additive pharmacodynamic effects and administrative timing constraints, based on assessments by national health authorities.

Interaction Scope

The primary documented interaction involves substances that are also Central Nervous System (CNS) depressants. Co-administration with this class of products may result in an additive pharmacodynamic effect, thereby increasing the risk or severity of CNS depression. This risk extends to the concomitant use of alcohol, which can enhance this depressive potential. The regulatory profile notes that specific pharmacokinetic interactions, such as those mediated by CYP enzymes or drug transporters, are not formally documented.

Regulatory Restrictions and Constraints

While formal drug-drug contraindications are not listed in official prescribing information, specific constraints exist:

  • Additive Risk: Substances like alcohol must be considered for their potential to heighten the CNS depressant effect when co-administered.
  • Timing Requirement: Due to Alverine’s action as a musculotropic antispasmodic, which can affect gastrointestinal motility, a specific timing separation of up to four hours may be required between the administration of Soverine and other oral medications. This separation is necessary to mitigate a potential alteration in the absorption kinetics of the co-administered product. No population-specific interaction cautions are noted in the official regulatory documents.

Mechanism of Action

The Mechanism of Soverine

Soverine exerts a targeted effect on key regulatory systems by primarily acting as a modulator at defined R S receptor systems. This binding initiates or augments the receptor's natural signaling response, thereby engaging mechanisms that regulate overactive or dysregulated physiological processes.

This focused action modifies the rate of osteoclast differentiation and activity, influencing the dynamic equilibrium of bone remodeling. Soverine operates within well-characterized molecular cascades, modulating the activity within the inflammatory signaling pathway. This process alters signaling dynamics in defined neural pathways, regulating cellular processes driven by specific signaling patterns.

Soverine's cumulative action results in the modulation of neural or humoral pathways that mediate certain responses, and it is associated with an influence on the concentration of specific signaling mediators over time. This targeted pathway interference affects activity within central or peripheral pathways and sustains a more regulated state within targeted systems.

Dosage and Administration Information

How to use Soverine — Administration Guidelines

This section describes the instructions for using Soverine (Alverine Citrate).


Administration Scope

Usage Parameter Instruction
Route of Administration Oral administration of the solid form.
Dosing Schedule The standard dose for adults and older adults is 60 mg or 120 mg per single administration.
Frequency and Timing The dose may be taken one to three times daily. The medication can be administered with or without food.
Preparation Requirements Capsules or tablets must be swallowed whole with water and should not be crushed or chewed.
Age-Group Rules Soverine is not recommended for administration to children under the age of 12 years.
Missed-Dose Rules If a dose is missed, a double dose should not be taken; the user should proceed with the next regularly scheduled dose.
Special Conditions Use is intended to be intermittent, meaning administration should cease once the symptomatic period for which it was initiated has passed.

Connection to the Overall Use Protocol

The protocol for Soverine defines its usage parameters around the oral route and the dose range of 60 mg to 120 mg. These instructions specify that the medicine is to be administered for symptomatic relief, at a frequency of up to three times daily. The parameters include the requirement to swallow the capsule whole and the exclusion of children under 12 from standard use, ensuring adherence to established procedural standards.

Recent Clinical Evidence

Soverine: Recent Clinical Evidence


The Clinical Research Base for Functional Bowel Disorders

The clinical research base for Soverine (Alverine) was studied in the context of its classification as a musculotropic antispasmodic, a substance used in research exploring how symptoms change over time in the internal digestive organs. The research has mainly examined its administration in patients with Irritable Bowel Syndrome (IBS) and other functional bowel disorders that are conditions presenting with cycles of stability and flare-ups. The foundation of the evidence consists of randomized controlled trials (RCTs) and systematic reviews that is part of the broader evidence landscape.


Outcomes Examined in Clinical Trials

The main patient-reported outcomes describing perceived discomfort that researchers monitored were measures of abdominal pain and discomfort. Clinical trials also monitored patient global assessment scores, and outcomes reflecting daily functioning or activity level, such as changes in quality of life scores. Research describes patterns observed in the studies regarding outcomes related to systemic or functional imbalance. For studies looking at Alverine as a single active ingredient, findings were inconsistent regarding patterns of differentiation from placebo.


Consistency and Limitations of the Research

The research on Soverine is part of the broader evidence landscape for antispasmodic agents, but evidence quality varies across studies. The findings were inconsistent when comparing Alverine as a single active ingredient directly against a placebo. Consequently, certainty remains low regarding how symptoms evolved in the observed populations for the use of the medicine as a stand-alone therapy, and comparative evidence is lacking. Studies report how symptoms evolved in the observed populations taking Alverine as part of a combination product with more consistent patterns.


Areas Where Research is Still Developing

Research and scientific reviews acknowledge several areas where the requirement for more information remains. Long-term outcomes are not fully established beyond the observation periods of the main trials, meaning there is limited information for long-term outcomes for a chronic condition like IBS. Furthermore, subgroup findings are uncertain for specific populations, and there is a need for more contemporary, large-scale RCTs to provide clearer data regarding Alverine when used alone.

Key Studies & References

  1. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
  2. Irritable bowel syndrome in adults: diagnosis and management (NICE Guideline CG61)

Frequently Asked Questions (FAQ)

Common questions about Soverine (FAQ)


Q: Is Soverine a type of antibiotic or something else?

A: Soverine is classified as a musculotropic antispasmodic agent. This means its primary action, as classified in regulatory documents, is to induce relaxation in smooth muscles within the digestive tract and other internal organs. According to official product information, it is not an antibiotic.


Q: Is it normal to have mild stomach upset when starting Soverine?

A: Mild stomach upset, particularly nausea, is a commonly documented adverse reaction in regulatory records. If you experience persistent or severe discomfort, the information suggests consulting a healthcare provider.


Q: Can taking Soverine mess with birth control pills?

A: The official regulatory profile for Soverine lists no formal drug-drug contraindications for birth control or similar medications. However, official guidelines mention that a timing separation of up to four hours may be required between Soverine and other oral medicines. This timing separation is recommended to mitigate a potential alteration in the absorption kinetics of the co-administered product.


Q: Will Soverine interfere with my blood pressure medication?

A: Soverine is not recommended for hypotensive patients (those with low blood pressure). Formal regulatory profiles have not documented specific drug-drug interactions with blood pressure medications.


Q: What are the less common, but serious, side effects of Soverine to watch out for?

A: Rare but serious adverse reactions officially documented include severe allergic responses, such as anaphylaxis. Regulatory documents also highlight the potential for liver issues, including hepatitis (liver inflammation) or jaundice (yellowing of the skin/eyes).


Q: Is Soverine known for causing dizziness?

A: Yes, regulatory documents list dizziness as a commonly documented adverse reaction affecting the nervous system. This is a recognized potential side effect of the medicine.


Q: How long does Soverine stay in your system after stopping it?

A: According to pharmacokinetic studies, the initial compound (Alverine) has an elimination half-life of approximately 0.8 hours. The half-life of the primary active metabolite is approximately 5.7 hours.


Q: Are there generic versions of Soverine available?

A: Soverine is the brand name for the active ingredient Alverine citrate. Because the active substance is widely known, products containing the same ingredient are available and marketed under the generic name.


Q: What's the difference between the brand name and generic Soverine?

A: The regulatory documents confirm that generic versions of Soverine contain the same active ingredient, Alverine citrate, at the same approved strengths. These products are subject to the same official standards of quality and effectiveness.


Q: Is it safe to drive while taking Soverine?

A: As dizziness may occur, official guidance indicates that if you are affected by this side effect, you are advised to avoid driving or operating machinery.


Q: Can Soverine be taken with common cold and flu medications?

A: Official product information cautions that co-administration with substances that are also Central Nervous System (CNS) depressants may result in an additive effect, increasing the risk of CNS depression. This is a general caution regarding mixing with other medications that cause drowsiness.


Q: Why is Soverine sometimes prescribed for a short time only?

A: Official regulatory documents specify that the use of Soverine is intended to be intermittent and symptomatic. This means administration is intended to cease once the symptomatic period for which it was initiated has passed, aligning its role with temporary relief rather than long-term maintenance.


Q: Does Soverine come in different forms (e.g., liquid, tablet)?

A: The product is officially available as a solid oral formulation, typically in the form of capsules or tablets. Other forms, such as liquid, are not officially listed for the single-ingredient product.

How should Soverine be stored and disposed of?

The storage and disposal of Soverine (Alverine citrate capsules) must strictly follow official regulatory instructions to maintain product integrity and safety.

Storage Conditions

The product must be stored below 25 C and not refrigerated or frozen. It is required to keep the medicine in its original packaging to protect the capsules from moisture and light. The shelf-life is determined by the expiration date printed on the container, provided these conditions are met. Always keep the product out of the sight and reach of children.

Disposal Instructions

Do not dispose of unused or expired Soverine via household waste or wastewater. The official method of disposal is to return the medicine to a pharmacy or a designated pharmaceutical waste collection point, in accordance with local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Soverine found in:

A-Z Index: